UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 2015
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware |
| 000-53072 |
| 41-2254389 |
|
(State or Other Jurisdiction |
| (Commission File Number) |
| (IRS Employer Identification No.) | ||
of Incorporation) |
|
|
|
| ||
21250 Hawthorne Blvd., Suite 800, Torrance, CA 90503
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code 310-214-0065
20725 S. Western Avenue, Suite 136 Torrance, CA 90501
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Departure of Directors or Certain Officers.
On January 9, 2015, Emmaus Life Sciences, Inc. (the “Company”) received notice from Mr. Duane Kurisu of his resignation from the Board of Directors of the Company. Mr. Kurisu’s resignation was not due to any disagreement with the Company and, in accordance with the Company’s By-laws, was effective on January 9, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EMMAUS LIFE SCIENCES, INC. | |||
|
| |||
|
| |||
Date: January 15, 2015 |
| |||
|
| |||
|
| |||
| By: | /s/ Peter Ludlum |
| |
| Name: | Peter Ludlum | ||
| Title: | Chief Financial Officer | ||